Advancements in Charcot-Marie-Tooth Disease Research and Awareness in the United States
Charcot-Marie-Tooth (CMT) disease, a hereditary neurological disorder affecting approximately 135,000 individuals in the United States, has seen significant developments in research and public awareness initiatives in recent years.
Innovative Research and Clinical Trials
In September 2023, the Muscular Dystrophy Association (MDA) and the Charcot-Marie-Tooth Association (CMTA) announced a collaborative research grant of $299,992. This three-year study, led by Dr. Alexia Kagiava at the Cyprus Institute of Neurology & Genetics, aims to develop a non-viral gene therapy using nanoparticles to target Schwann cells in CMT1X patients. The approach is anticipated to offer a safer and more targeted alternative to existing gene delivery methods.
Hackensack University Medical Center has been at the forefront of clinical trials for CMT treatments. Dr. Florian P. Thomas, chair of the Neuroscience Institute, led the first U.S. clinical trial of PXT3003, a combination medication comprising baclofen, naltrexone, and D-sorbitol. The trial demonstrated that high-dose PXT3003 is safe, well-tolerated, and improves neuromuscular function in CMT1A patients. Additionally, the center has initiated a third clinical trial, furthering its commitment to advancing CMT therapies.
In March 2023, researchers at the Daegu Gyeongbuk Institute of Science and Technology developed a technology utilizing electric stimulation to correct the abnormal distribution of peripheral myelin protein 22 (PMP22), a primary cause of CMT1A. This non-pharmacological approach has the potential to offer a novel treatment avenue with minimal side effects.
Community Engagement and Awareness
On October 4, 2025, a walk was held in Blacksburg, Virginia, to raise awareness for CMT. Organized by local resident Karen Brown, the event emphasized the importance of community support and visibility for those affected by the disease. Proceeds from the walk were donated to the CMTA to support ongoing research and patient support initiatives.
Emerging Therapeutic Developments
In October 2025, Revir Therapeutics Inc.’s RTX-117 received orphan drug designation from the FDA for the treatment of CMT. RTX-117 is a small-molecule therapy designed to activate eIF2B, aiming to restore normal protein expression and address the underlying causes of the disease.
Furthermore, in September 2025, Neucore Bio Inc. secured a $350,000 grant from the National Center for Advancing Translational Sciences to evaluate its targeted exosome platform. This platform is intended to deliver RNA-based therapy specifically for CMT1A, representing a promising advancement in gene therapy approaches.
These developments underscore a concerted effort within the United States to advance research, develop effective treatments, and enhance public awareness for Charcot-Marie-Tooth disease, offering hope to those affected by this challenging condition.
